Items Tagged with 'Pfizer'
Purchase ceiling raised for two stock picks.
In light of significant recent developments, The Turnaround Letter is raising its maximum buy price for these large cap purchase recommendations.Read More
PFE Complete $11.85 billion Sale
On November 30, Pfizer Inc. (NYSE: PFE) announced that it has completed the sale of its Nutrition business to Nestlé for $11.85 billion in cash, following the conclusion of the required regulatory process in most markets.
PFE Announces Revenues of $14.0 billion
On November 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2012. Third-quarter 2012 revenues were $14.0 billion, a decrease of 16% compared with $16.6 billion in the year-ago quarter, which reflects an operational decline of $1.9 billion, or 12%, and the unfavorable impact of foreign exchange of $699 million, or 4%.
PFE Reports Second Quarter 2012 Revenues of $15.1 Billion
On July 31, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2012.
PFE Obtains FDA Approval for Lyrica
On June 21, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved the use of Lyrica® (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury.
PFE Reports 7% Revenue Decrease
On May 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2012.
PFE to Divest Nutrition Business
On April 23, 2012, Pfizer Inc. (NYSE: PFE) announced that it has entered into an agreement to divest its Nutrition business to Nestle for $11.85 billion in cash.
Pfizer Buys Vitamin C Icon
On February 27, 2012, Pfizer Inc. (NYSE:PFE) announced the acquisition of privately-held Alacer Corp....
On February 1, 2012, Pfizer Inc. (NYSE: PFE) announced that it has voluntarily recalled 14 lots of Lo/Ovral®-28 (norgestrel and ethinyl estradiol)Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic) for customers in the U.S. market.
On January 27, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
Your Financial Security is Serious Business...
so why should you trust The Turnaround Letter?
Ranked Among Top-2 for 15-Yr. Returns: Turnaround Letter's 12.1% vs. S&P's 2.5%
28+ Years of Turnaround Investing Experience & Reliable Stock Market Advice
Diverse Monthly Stock Picks Personally Selected by George Putnam
Distressed Investing Blog
Looking to cash in on timely tax loss selling and portfolio window dressing? These 10 year-end bounce stock picks represent the worst performers in the S&P 500 during calendar 2014, adjusted somewhat so that there is good diversification by industry group.
George Putnam has always followed the same straight-forward and highly-profitable investment philosophy. He published his first Turnaround Letter issue back in 1986, and readers have seen extraordinary long-term stock profit ever since.
In fact, 12 of 2014's 13 closed-out purchase recommendations saw gains--with five of those enjoying total returns greater than 100%. The Turnaround Letter's average return for 2014's stock picks is +82%:
2014 Closed Out Purchase Recommendations
* Calculation includes dividends and price changes between purchase recommendation and current price.
Copyright © All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing.